In addition, several p38α mitogen-activated protein kinase (MAPK) inhibitors can be used to treat COPD, and these drugs significantly reduce the in vivo expression of MAPK-driven inflammatory mediators (such as TNF-α and IL-1β) in mouse models of acute inflammation [22]. This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.